Skip to main
HURA
HURA logo

HURA Stock Forecast & Price Target

HURA Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

TuHURA Biosciences is advancing towards a Phase 3 registration trial for its personalized cancer vaccine candidate, IFx-2.0, which targets resistance to established cancer immunotherapies, particularly by complementing Keytruda in treating advanced Merkel Cell Carcinoma. The company's strategic focus on addressing primary resistance in immuno-oncology positions it favorably within a growing market, suggesting significant potential for revenue generation as clinical results progress positively. Furthermore, the innovative approach of IFx-2.0 enhances its prospects for successful commercialization, reflecting strong momentum in the company’s operational and financial trajectory.

Bears say

TuHURA Biosciences reported a net loss of $0.15 per share in 1Q25, which was consistent with previous estimates of a $0.12 loss, indicating ongoing financial challenges. The company faces several significant risks that could adversely affect its financial performance and stock outlook, including potential negative clinical results for its personalized cancer vaccine candidate, IFx-2.0, and delays in advancing pipeline candidates toward regulatory approval. Additionally, competitive pressures from other checkpoint inhibitors and the risk of long-term dilution further compound the negative sentiment surrounding TuHURA's stock prospects.

HURA has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of TuHURA Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About TuHURA Biosciences Inc (HURA) Forecast

Analysts have given HURA a Strong Buy based on their latest research and market trends.

According to 2 analysts, HURA has a Strong Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

TuHURA Biosciences Inc (HURA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.